Cellceutix Corporation is a clinical-stage pharmaceutical company. The Company is focused on developing and/or acquiring small molecule therapies. The Company's clinical programs include Kevetrin, Prurisol, Brilacidin and Brilacidin-OM. It is evaluating investigational drugs Kevetrin (thioureidobutyronitrile) for the treatment of cancers, Prurisol (KM-133) for the treatment of psoriasis, and Brilacidin for the treatment of skin infections and prevention of oral mucositis. The Company has also planned to conduct a Phase II clinical trial of topical host-defense proteins (HDP) mimic for the treatment of hidradenitis suppurativa (HS). It is also formulating and conducting pre-clinical experiments on topical Brilacidin for use in topical applications, such as diabetic foot ulcer infections, and for ear-related infections, such as otitis externa or draining otitis media. Other compounds owned by the Company are KM 391, KM 277, KM 278, KM 362, KM-3174 and KM-732.